KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)

Boston Scientific's Current Deferred Revenue history spans 2 years, with the latest figure at $147.0 million for Q3 2020.

On a quarterly basis, Current Deferred Revenue changed N/A to $147.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $147.0 million, a N/A change, with the full-year FY2019 number at $144.0 million, changed N/A from a year prior.
Current Deferred Revenue hit $147.0 million in Q3 2020 for Boston Scientific, up from $143.0 million in the prior quarter.
Over the last five years, Current Deferred Revenue for BSX hit a ceiling of $251.0 million in Q1 2020 and a floor of $143.0 million in Q2 2020.